Evidence map›Paper›PMID 35200628›Full record

ArticleMarine drugs2022

Study of the Structure-Activity Relationship of an Anti-Dormant Mycobacterial Substance 3-(Phenethylamino)Demethyl(oxy)aaptamine to Create a Probe Molecule for Detecting Its Target Protein.

Yuji Sumii, Kentaro Kamiya, Takehiko Nakamura, Kenta Tanaka, Takumi Kaji, Junya Mukomura, Naoyuki Kotoku, Masayoshi Arai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Oxidative Cyclization atMarine drugs · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yuji SumiiGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.ORCID 0000-0003-3900-1089
Kentaro KamiyaGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
Takehiko NakamuraGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
Kenta TanakaGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
Takumi KajiGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
Junya MukomuraCollege of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-higashi, Kusatsu, Shiga 525-8577, Japan.
Naoyuki KotokuGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
Masayoshi AraiGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.ORCID 0000-0003-2771-1948
The University of Osaka · JPRitsumeikan University · JP

Funding

Japan Agency for Medical Research and Development JP21am0101084Japan Society for the Promotion of Science 18H02096, 21H02069Kobayashi International Scholarship Foundation N/A
6 · The paper itself

Abstract

The current tuberculosis treatment regimen is long and complex, and its failure leads to relapse and emergence of drug resistance. One of the major reasons underlying the extended chemotherapeutic regimen is the ability of

Indexed as

AnimalsAntitubercular AgentsDrug Resistance, BacterialMolecular ProbesMycobacterium tuberculosisNaphthyridinesPoriferaStructure-Activity Relationship3-(phenethylamino)demethyl(oxy)aaptamineAntitubercular AgentsMolecular ProbesNaphthyridinesaaptamineantibioticsdormantprobe moleculestructure–activity relationshiptuberculosis

Identifiers

PMID35200628
PMCPMC8879696
OpenAlexW4210300099

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.